Cabazitaxel for the treatment of prostate cancer

Author： Michielsen Dirk PJ   Braeckman Johan G   Denis Louis  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.6, 2011-04, pp. : 977-982

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Prostate cancer: abiraterone acetate beats cabazitaxel

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Hormonal treatment for prostate cancer

By Harris K.A.   Small E.J.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 493-510

Informa Healthcare

Access to resources Recommend Favorite

Targeting angiogenesis for the treatment of prostate cancer

By Antonarakis Emmanuel S   Carducci Michael A  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 365-376

Informa Healthcare

Access to resources Recommend Favorite

An evaluation of bicalutamide in the treatment of prostate cancer

By Schellhammer Paul F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1313-1328

Informa Healthcare

Access to resources Recommend Favorite